Tate Jacqueline E, Curns Aaron T, Cortese Margaret M, Weintraub Eric S, Hambidge Simon, Zangwill Kenneth M, Patel Manish M, Baggs James M, Parashar Umesh D
Centers for Disease Control and Prevention, 1600 Clifton Rd, NE Mail Stop A47, Atlanta, GA 30333, USA.
Pediatrics. 2009 Mar;123(3):744-9. doi: 10.1542/peds.2008-1200.
With the implementation of a new rotavirus immunization program in the United States in 2006, determining the potential health benefits of rotavirus vaccination is important. We estimated the burden of acute gastroenteritis hospitalizations and emergency department visits in US children that are potentially preventable by rotavirus vaccination.
We conducted a retrospective cohort analysis of children who in 1998-1999 were eligible to receive a now-withdrawn rotavirus vaccine (RotaShield) and were continuously enrolled in 1 of 6 managed care organizations in the Vaccine Safety Datalink. Estimates of vaccine effectiveness against all-cause gastroenteritis hospitalizations and emergency department visits adjusted according to month of birth, gender, and managed care organizations were calculated as 1 minus the risk ratio of outcomes among children in different dose groups. The burden of acute gastroenteritis prevented by vaccination was compared with the rotavirus burden estimated by 2 previously used indirect methods.
The effectiveness of a full 3-dose RotaShield series over a 1-year follow-up period was 83% against all-cause gastroenteritis hospitalizations and 43% against all-cause gastroenteritis emergency department visits. An increasing number of doses improved the effectiveness in preventing gastroenteritis hospitalizations, but no clear trend was observed between number of doses and effectiveness in prevention of gastroenteritis emergency department visits. The proportion of gastroenteritis hospitalizations and emergency department visits prevented by vaccination was substantially greater than the 48% to 53% of year-round hospitalizations and 33% of emergency department visits estimated to result from rotavirus by indirect methods.
The withdrawn rotavirus vaccine was highly effective in preventing hospitalizations and emergency department visits for all-cause acute gastroenteritis and the health benefits of vaccination against rotavirus may be greater than previously estimated.
随着2006年美国实施新的轮状病毒免疫计划,确定轮状病毒疫苗的潜在健康益处非常重要。我们估计了美国儿童中可通过轮状病毒疫苗预防的急性胃肠炎住院和急诊就诊负担。
我们对1998 - 1999年有资格接种现已停用的轮状病毒疫苗(RotaShield)且持续加入疫苗安全数据链中6个管理式医疗组织之一的儿童进行了回顾性队列分析。根据出生月份、性别和管理式医疗组织调整后,针对全因胃肠炎住院和急诊就诊的疫苗效力估计值计算为1减去不同剂量组儿童结局的风险比。将疫苗预防的急性胃肠炎负担与之前使用的两种间接方法估计的轮状病毒负担进行比较。
在1年的随访期内,完整3剂RotaShield系列疫苗针对全因胃肠炎住院的效力为83%,针对全因胃肠炎急诊就诊的效力为43%。接种剂量增加可提高预防胃肠炎住院的效力,但在接种剂量与预防胃肠炎急诊就诊的效力之间未观察到明显趋势。疫苗预防的胃肠炎住院和急诊就诊比例显著高于间接方法估计的全年住院病例的48%至53%以及急诊就诊病例的33%。
已停用的轮状病毒疫苗在预防全因急性胃肠炎住院和急诊就诊方面非常有效,接种轮状病毒疫苗的健康益处可能比之前估计的更大。